Further correlation analyses demonstrated significant associations between ERBB2 positivity and tumor progression (p = 0.028), and the presence of an ERBB2 amplification (p < 0.001), but not for age, sex, growth pattern, necrosis, or other clinicopathological parameters, such as tumor stage, lymph node metastasis, distant metastasis, and lymphovascular or perineural invasion (p > 0.05) (Table 3). Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.